The U.S. fusion biopsy market size was evaluated at USD 159.69 million in 2025 and is expected to grow around USD 341.58 million by 2035, registering a CAGR of 7.9% from 2026 to 2035. Growing due to strong presence of advanced healthcare technologies and increasing preference for minimally invasive diagnostic methods.

U.S. Fusion Biopsy Market Statical Scope

In the U.S. strong technological innovation is driving the fusion biopsy market particularly in AI-based diagnostic support and MRI-targeted biopsy systems. Adoption rates are being strengthened by the growing preference for minimally invasive procedures and precision medicine. Growth is also being supported by ongoing clinical research and the approval of cutting-edge biopsy equipment. Wider patient access is made possible by high healthcare spending and robust insurance coverage. Product innovation and adoption are being further accelerated by the presence of top medical technology companies. Increasing integration of robotics and AI-assisted workflow systems is further improving procedural accuracy and efficiency. Rising investments in prostate cancer research programs are also contributing to continuous technological advancements.

The market is fueled by the high incidence of prostate cancer; the robust presence of cutting-edge medical device manufacturers is the quick adoption of AI-enabled fusion biopsy systems. Technological advancements and ongoing clinical research are increasing workflow efficiency and diagnostic accuracy. Early screening adoption and robust insurance coverage contribute to market expansion. Increasing use of real-time imaging technologies is further enhancing biopsy precision and reducing diagnostic errors. Strong collaboration between healthcare providers and technology developers is also supporting faster commercialization of innovative biopsy solutions.

U.S. Fusion Biopsy Market Share, By Biopsy Route, 2025 (%)

• Transrectal - Transrectal segment dominated the market in 2025 with a share of 55%, driven by well-established hospital-based practices with high clinical adoption and procedural efficiency. The accuracy of diagnoses is being further improved by ongoing technological advancements. Strong access to cutting edge medical facilities is another factor in bolstering segment dominance. Growing integration of AI-assisted biopsy platforms is also supporting improved workflow efficiency. Rising investments in precision diagnostic technologies are further driving segment growth.
• Transperineal - Transperineal segment emerged as the fastest growing with a share of 45% driven by a growing desire for infection free practices and enhanced diagnostic accuracy. Uptake is being accelerated by the increasing use of sophisticated imaging fusion platforms Adoption is also being aided by increasing physician awareness of the advantages of patient safety. Rising investments in precision medicine are further contributing to segment expansion. Growing demand for advanced outpatient urology procedures is also supporting market adoption.

U.S. Fusion Biopsy Market Share, By End Use, 2025 (%)

• Hospitals - Hospitals dominated the market in 2025 with a share of 49% driven by a large patient volume, robust infrastructure, and cutting-edge imaging capabilities. The use of AI assisted diagnostics tools is bolstering hospital leadership even more. The growth of the market is also aided by the existence of top medical facilities. Increasing clinical research activities related to prostate cancer diagnostics are also supporting hospital market growth. Expanding deployment or robotic assisted biopsy systems is further enhancing hospital efficiency.
• Diagnostic Centers - Diagnostic centers showed notable growth with a share of 31%, driven by the expansion of specialized cancer screening facilities and the growing demand for outpatient diagnostics. Growth is being accelerated by patients growing preference for prompt diagnostic services. Adoption is also being aided by advances in MRI imaging technology. Availability of high-resolution imaging systems is also improving diagnostic efficiency.
• Ambulatory Care Centers - Ambulatory care centers recorded steady growth with a share of 20%, driven by a growing trend toward minimally invasive care models and more affordable outpatient procedures. Adoption is being aided by growing healthcare consumerism. Demand in this segment is also being boosted by easier access or same-day diagnostic services. Improved insurance coverage for outpatient diagnostic procedures is also contributing to market growth.

Competitive Landscape

U.S. fusion biopsy market competitive landscape is highly competitive with leading companies such as GE HealthCare, Philips Healthcare, Exact Imaging, and Focal Healthcare. These companies are focusing on technological advancements, AI-enabled fusion biopsy platforms, and workflow automation solutions to improve diagnostic precision and strengthen their market share across the country. To improve outcomes and procedural accuracy, companies are investing more in clinical trials, software integration, and advanced imaging platforms. The growing need for minimally invasive prostate cancer diagnostics is also driving continuous product innovation

Segments Covered in the Report

By Biopsy Route

• Transrectal
• Transperineal

By End Use

• Hospitals
• Diagnostic Centers
• Ambulatory Care Centers